• Aldabe R, Barco A, Carrasco L. 1996. Membrane permeabilization by poliovirus proteins 2B and 2BC. J. Biol. Chem., 271: 23134-23137.

  • Ang PY, Chong CWH, Alonso S. 2021. Viral determinants that drive Enterovirus-A71 fitness and virulence. Emerg. Microb. Infect., 10: 713-724.

  • Arena MP, Elmastour F, Sane F, Drider D, Fiocco D, Spano G, Hober D. 2018. Inhibition of coxsackievirus B4 by Lactobacillus plantarum. Microbiol. Res., 210: 59-64.

  • Arita M, Ami Y, Wakita T, Shimizu H. 2008. Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model. J. Virol., 82: 1787-1797.

  • Arola A, Kalimo H, Ruuskanen O, Hyypia T. 1995. Experimental myocarditis induced by two different coxsackievirus B3 variants: aspects of pathogenesis and comparison of diagnostic methods. J. Med. Virol., 47: 251-259.

  • Baggen J, Thibaut HJ, Strating J, van Kuppeveld FJM. 2018. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol., 16: 368-381.

  • Baxter NJ, Roetzer A, Liebig HD, Sedelnikova SE, Hounslow AM, Skern T, Waltho JP. 2006. Structure and dynamics of coxsackievirus B4 2A proteinase, an enyzme involved in the etiology of heart disease. J. Virol., 80: 1451-1462.

  • Bengs S, Marttila J, Susi P, Ilonen J. 2015. Elicitation of T-cell responses by structural and non-structural proteins of coxsackievirus B4. J. Gen. Virol., 96: 322-330.

  • Benkahla MA, Alidjinou EK, Sane F, Desailloud R, Hober D. 2018. Fluoxetine can inhibit coxsackievirus-B4 E2 in vitro and in vivo. Antivir. Res., 159: 130-133.

  • Bissel SJ, Winkler CC, DelTondo J, Wang G, Williams K, Wiley CA. 2014. Coxsackievirus B4 myocarditis and meningoencephalitis in newborn twins. Neuropathology, 34: 429-437.

  • Caggana M, Chan P, Ramsingh A. 1993. Identification of a single amino acid residue in the capsid protein VP1 of coxsackievirus B4 that determines the virulent phenotype. J. Virol., 67: 4797-4803.

  • Chang CK, Wu SR, Chen YC, Lee KJ, Chung NH, Lu YJ, Yu SL, Liu CC, Chow YH. 2018. Mutations in VP1 and 5'-UTR affect enterovirus 71 virulence. Sci. Rep., 8: 6688.

  • Cordey S, Petty TJ, Schibler M, Martinez Y, Gerlach D, van Belle S, Turin L, Zdobnov E, Kaiser L, Tapparel C. 2012. Identification of site-specific adaptations conferring increased neural cell tropism during human enterovirus 71 infection. PLoS Pathog., 8: e1002826.

  • Dai J, Xu D, Yang C, Wang H, Chen D, Lin Z, Qiu S, Zhang L, Li X, Tian X, Liu Q, Cui Y, Zhou R, Liu W. 2023. Severe pneumonia and pathogenic damage in human airway epithelium caused by Coxsackievirus B4. Emerg. Microb. Infect., 12: 2261560.

  • De Palma AM, Thibaut HJ, Li S, Van Aelst I, Dillen C, Swinnen M, Verbeken E, Neyts J, Opdenakker G. 2009. Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis. J. Pathol., 217: 633-641.

  • Di Lorenzo TP, Peakman M, Roep BO. 2007. Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol., 148: 1-16.

  • Dong ZP, Wang Q, Zhang ZJ, Carr MJ, Li D, Shi WF. 2018. Murine model of acute myocarditis and cerebral cortical neuron edema induced by coxsackievirus B4. Zool. Res., 39: 52-57.

  • El Kfoury KA, Romond MB, Scuotto A, Alidjinou EK, Dabboussi F, Hamze M, Engelmann I, Sane F, Hober D. 2017. Bifidobacteria-derived lipoproteins inhibit infection with coxsackievirus B4 in vitro. Int. J. Antimicrob. Agents, 50: 177-185.

  • Garmaroudi FS, Marchant D, Hendry R, Luo H, Yang D, Ye X, Shi J, McManus BM. 2015. Coxsackievirus B3 replication and pathogenesis. Future Microbiol., 10: 629-653.

  • Gharbi J, Hadj Hassine I, Hassine M, Al-Malki M, Al-Yami A, Al-Bachir A, Ben M'hadheb M. 2023. Viral protein VP1 Virus-like Particles (VLP) of CVB4 induces protective immunity against lethal challenges with diabetogenic E2 and wild type JBV strains in mice model. Viruses, 15: 878.

  • Gradi A, Svitkin YV, Imataka H, Sonenberg N. 1998. Proteolysis of human eukaryotic translation initiation factor eIF4GII, but not eIF4GI, coincides with the shutoff of host protein synthesis after poliovirus infection. Proc. Natl. Acad. Sci. U. S. A., 95: 11089-11094.

  • Grodums EI, Dempster G. 1959. Myocarditis in experimental Coxsackie B-3 infection. Can. J. Microbiol., 5: 605-615.

  • Hierholzer JC, Mostow SR, Dowdle WR. 1972. Prospective study of a mixed coxsackie virus B3 and B4 outbreak of upper respiratory illness in a children's home. Pediatrics, 49: 744-752.

  • Hindersson M, Orn A, Harris RA, Frisk G. 2004. Strains of coxsackie virus B4 differed in their ability to induce acute pancreatitis and the responses were negatively correlated to glucose tolerance. Arch. Virol., 149: 1985-2000.

  • Hu YF, Du J, Zhao R, Xue Y, Yang F, Jin Q. 2012. Complete genome sequence of a recombinant coxsackievirus B4 from a patient with a fatal case of hand, foot, and mouth disease in Guangxi, China. J. Virol., 86: 10901-10902.

  • Jenkins O, Booth JD, Minor PD, Almond JW. 1987. The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae. J. Gen. Virol., 68 (Pt 7): 1835-1848.

  • Jiang Z, Zhang Y, Lin H, Cheng Q, Lu X, Liu W, Zhou R, Zhong B, Tian X. 2021. A 10-Day-Old murine model of coxsackievirus A6 infection for the evaluation of vaccines and antiviral drugs. Front. Immunol., 12: 665197.

  • Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA. 2006. Enterovirus surveillance--United States, 1970-2005. MMWR Surveill Summ, 55: 1-20.

  • Lamphear BJ, Yan R, Yang F, Waters D, Liebig HD, Klump H, Kuechler E, Skern T, Rhoads RE. 1993. Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J. Biol. Chem., 268: 19200-19203.

  • Lin JY, Chen TC, Weng KF, Chang SC, Chen LL, Shih SR. 2009. Viral and host proteins involved in picornavirus life cycle. J. Biomed. Sci., 16: 103.

  • Lin YL, Cheng PY, Chin CL, Chuang KT, Lin JY, Chang N, Pan CK, Lin CS, Pan SC, Chiang BL. 2023. A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge. J. Biomed. Sci., 30: 96.

  • Liu Q, Wang H, Xuan X, Liu H, Tang B, Zhou Z, Zhang L, Qiu S, Li X, Tian X, Zhou R, Liu W. 2025. Construction and in vitro and in vivo analysis of coxsackievirus B4 reporter viruses: attenuated virulence but highly efficient for antiviral drug screening and evaluation. J. Med. Virol., 97: e70433.

  • Liu W, Zhang L, Cai Y, Zhang Q, Chen D, Qiu S, Wang Y, Xu D, Gu S, Li X, Dai J, Liu Q, Zhou R, Tian X. 2022. Human adenovirus subtype 21a isolates from children with severe lower respiratory illness in China. Front. Microbiol., 13: 924172.

  • Liu Y, Chen J, Zhang M, Guo W, Feng C, Liu J, Xu L, Gao N, Ma S. 2023. Coxsackievirus B: the important agent of hand, foot, and mouth disease. J. Med. Virol., 95: e28669.

  • Liu Z, Wei F, Chen LJ, Xiong HR, Liu YY, Luo F, Hou W, Xiao H, Yang ZQ. 2013. In vitro and in vivo studies of the inhibitory effects of emodin isolated from Polygonum cuspidatum on Coxsakievirus B4. Molecules, 18: 11842-11858.

  • Liu ZW, Zhuang ZC, Chen R, Wang XR, Zhang HL, Li SH, Wang ZY, Wen HL. 2019. Enterovirus 71 VP1 protein regulates viral replication in SH-SY5Y cells via the mTOR autophagy signaling pathway. Viruses, 12.

  • Mao Q, Hao X, Hu Y, Du R, Lang S, Bian L, Gao F, Yang C, Cui B, Zhu F, Shen L, Liang Z. 2018. A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5. Emerg. Microb. Infect., 7: 185.

  • Nekoua MP, Bertin A, Sane F, Alidjinou EK, Lobert D, Trauet J, Hober C, Engelmann I, Moutairou K, Yessoufou A, Hober D. 2020. Pancreatic beta cells persistently infected with coxsackievirus B4 are targets of NK cell-mediated cytolytic activity. Cell. Mol. Life Sci., 77: 179-194.

  • Nekoua MP, Bertin A, Sane F, Gimeno JP, Fournier I, Salzet M, Engelmann I, Alidjinou EK, Hober D. 2021. Persistence of Coxsackievirus B4 in pancreatic β cells disturbs insulin maturation, pattern of cellular proteins, and DNA methylation. Microorganisms, 9, 1125.

  • Nekoua MP, Hober D. 2022. Coxsackievirus infection and associated diseases. Microorganisms, 10: 1566.

  • Porres ER, Werthammer J, Moss N, Bernstein JM, Belshe RB. 1985. Fatal coxsackievirus B4 infection in a neonate. South. Med. J., 78: 1254-1256.

  • Ramsingh A, Araki H, Bryant S, Hixson A. 1992. Identification of candidate sequences that determine virulence in Coxsackievirus B4. Virus Res., 23: 281-292.

  • Ramsingh AI, Caggana M, Ronstrom S. 1995. Genetic mapping of the determinants of plaque morphology of coxsackievirus B4. Arch. Virol., 140: 2215-2226.

  • Ramsingh AI, Collins DN. 1995. A point mutation in the VP4 coding sequence of coxsackievirus B4 influences virulence. J. Virol., 69: 7278-7281.

  • Stone VM, Hankaniemi MM, Laitinen OH, Sioofy-Khojine AB, Lin A, Diaz Lozano IM, Mazur MA, Marjomaki V, Lore K, Hyoty H, Hytonen VP, Flodstrom-Tullberg M. 2020. A hexavalent Coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci. Adv., 6: eaaz2433.

  • Tang C, Chen Y, Jin H, Lei L, Xiang Y, Cheng Y, Huang B. 2023. miR-342-5p targets CTNNBIP1 to promote enterovirus 71 replication. Microb. Pathog., 182: 106259.

  • Tracy S, Drescher KM. 2007. Coxsackievirus infections and NOD mice: relevant models of protection from, and induction of, type 1 diabetes. Ann. N. Y. Acad. Sci., 1103: 143-151.

  • van Kuppeveld FJ, Galama JM, Zoll J, van den Hurk PJ, Melchers WJ. 1996. Coxsackie B3 virus protein 2B contains cationic amphipathic helix that is required for viral RNA replication. J. Virol., 70: 3876-3886.

  • van Kuppeveld FJ, Hoenderop JG, Smeets RL, Willems PH, Dijkman HB, Galama JM, Melchers WJ. 1997. Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J., 16: 3519-3532.

  • Wang L, Dong C, Chen DE, Song Z. 2014. Coxsackievirus-induced acute neonatal central nervous system disease model. Int. J. Clin. Exp. Pathol., 7: 858-869.

  • Wang T, Wang C, Pang L, Zhang Y, Wang S, Liang X, Huang Z. 2024. Immunogenicity and protective efficacy of inactivated coxsackievirus B4 viral particles. Emerg. Microb. Infect., 13: 2337665.

  • Weng S, Zhu R, Wu Y, Xia N, Xu L, Cheng T. 2025. Research progress and application prospects of animal models of group B Coxsackievirus infections. Emerg. Microb. Infect., 14: 2441391.

  • Xiao J, Wang J, Lu H, Song Y, Sun D, Han Z, Li J, Yang Q, Yan D, Zhu S, Pei Y, Wang X, Xu W, Zhang Y. 2023. Genomic epidemiology and transmission dynamics of global coxsackievirus B4. Viruses, 15: 569.

  • Xiao J, Wang J, Zhang Y, Sun D, Lu H, Han Z, Song Y, Yan D, Zhu S, Pei Y, Xu W, Wang X. 2021. Coxsackievirus B4: an underestimated pathogen associated with a hand, foot, and mouth disease outbreak. Arch. Virol., 166: 2225-2234.

  • Yen MH, Lee JJ, Yeh CF, Wang KC, Chiang YW, Chiang LC, Chang JS. 2014. Yakammaoto inhibited human coxsackievirus B4 (CVB4)-induced airway and renal tubular injuries by preventing viral attachment, internalization, and replication. J. Ethnopharmacol., 151: 1056-1063.

  • You Y, Guo K, Ma M, Duan X, Xie Y, Jiang Y, Jia H, Han B. 2025. Single-Cell RNA sequencing reveals macrophage-endothelial cell crosstalk in viral Myocarditis. J. Med. Virol., 97: e70440.

  • Zell R, Delwart E, Gorbalenya AE, Hovi T, King AMQ, Knowles NJ, Lindberg AM, Pallansch MA, Palmenberg AC, Reuter G, Simmonds P, Skern T, Stanway G, Yamashita T, Ictv Report C. 2017. ICTV virus taxonomy profile: picornaviridae. J. Gen. Virol., 98: 2421-2422.

  • Zhang S, Xue X, Qiao S, Jia L, Wen X, Wang Y, Wang C, Li H, Cui J. 2023. Umifenovir epigenetically targets the IL-10 pathway in therapy against Coxsackievirus B4 infection. Microbiol. Spectr., 11: e0424822.

  • Zhang Z, Zhang X, Carr MJ, Zhou H, Li J, Liu S, Liu T, Xing W, Shi W. 2019. A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs. Emerg. Microb. Infect., 8: 1445-1455.

  • Zoll J, Heus HA, van Kuppeveld FJ, Melchers WJ. 2009. The structure-function relationship of the enterovirus 3'-UTR. Virus Res., 139: 209-216.